A Phase 4 interventional study of Proton Pump Inhibitor and Bismuth in Functional Dyspepsia and Scarred Peptic Ulcer, sponsored by Shanghai Jiao Tong University School of Medicine. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-06-04.
Sponsored by Shanghai Jiao Tong University School of Medicine · Phase 4, Interventional, and Treatment
The increase of antibiotic resistance to H. pylori causes failure of treatment. Furazolidone, amoxicillin and tetracycline are good candidates for rescue therapy since resistance to these three antimicrobials was rare. It is necessary to assess the efficacy and safety of these four bismuth-containing quadruple regimens with above antibiotics as empirical rescue therapies for H. pylori eradication.
193 studies on the registry are indexed under Peptic Ulcer; 31 are open to participants now.
This study's enrollment of 424 is above the median of 150 across 142 interventional studies indexed under Peptic Ulcer.
Browse Peptic Ulcer studies →Shanghai Jiao Tong University School of Medicine is the lead sponsor of 358 studies on the registry; 104 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
one of the four empirical rescue therapies
Drug: Proton Pump Inhibitor · Drug: Bismuth · Drug: Tetracycline · Drug: Furazolidone
one of the four empirical rescue therapies
Drug: Proton Pump Inhibitor · Drug: Bismuth · Drug: Tetracycline · Drug: Amoxicillin
one of the four empirical rescue therapies
Drug: Proton Pump Inhibitor · Drug: Bismuth · Drug: Furazolidone · Drug: Amoxicillin
Classical rescue therapy
Drug: Proton Pump Inhibitor · Drug: Bismuth · Drug: Metronidazole · Drug: Tetracycline
Also known as: Lansoprazole
Also known as: Bismuth potassium citrate
eradication rate of H. pylori
Time frame: 2 months
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Jiao Tong University School of Medicine